Opportunity Radar

← Back to search

Grant

Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

View on Grants.gov ↗ Sign in to save

Type
Grant
Notice type
CA
Agency
National Institutes of Health
Sub-agency
HHS-NIH11
Solicitation #
RFA-CA-27-005
Posted
Aug 31, 2026
Response due
Jan 11, 2027
Archive date
Mar 11, 2027
CFDA / Assistance listing
93.394,93.395
Award ceiling
$700,000
Total program funding
$4,400,000
Contact
GTN-contacts@nih.gov
Source
Grants.gov

Description

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.

Similar open opportunities